Abiraterone Acetate (Zytiga®)

 
Common name: Abiraterone Acetate
Brand name: Zytiga®


What is Abiraterone Acetate?

Abiraterone Acetate is a drug used to treat advanced prostate cancer (metastatic castrate resistant prostate cancer). Abiraterone acetate blocks the production of testosterone to stop the spread and growth of prostate cancer cells.

Abiraterone Acetate is used in combination with a corticosteroid (such as prednisone) and has been approved for the following uses:
  • It is given to men who previously received docetaxel chemotherapy after failure of androgen deprivation therapy.
  • It is also given to men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy.


How is Abiraterone Acetate administered?

Abiraterone Acetate is administered orally as a tablet.


What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. Below are some side effects experienced by those who received abiraterone acetate. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Diarrhea
  • Frequent urination
  • High blood pressure
  • Hot flashes
  • Joint pain
  • Low potassium (hypokalemia)
  • Muscle aches
  • Upset stomach

Is Abiraterone Acetate covered in my province or territory?

Abiraterone acetate is covered by provincial drug programs in:
  • Alberta
  • British Columbia
  • New Brunswick
  • Newfoundland & Labrador
  • Nova Scotia
  • Ontario
  • Quebec
  • Saskatchewan
Abiraterone acetate is not covered by provincial/territorial drug programs in:
  • Manitoba
  • Prince Edward Island
  • Nunavut
  • Northwest Territories
  • Yukon
The pan-Canadian Oncology Drug Review (pCODR) recommends funding abiraterone acetate (zytiga®).
To read pCODRs full recommendation, please click here.

For more information on pCODR, please visit www.pcodr.ca
 


Last Reviewed: July 2017

Donate Now!




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Rock the Road Raffle returns with its most valuable car to date

A 2018 Acura NSX to be prized by Prostate Cancer Canada and TADA at the AutoShow  
More

Prostate Cancer Canada and the Movember Foundation Announce $4M in Research Grants

Toronto, October 23, 2018 – Prostate Cancer Canada and the Movember Foundation today announced $4 million in funding to three Canadian researchers to predict how well prostate cancer will respond to treatment, based on men’s biological markers, specifically in their tumour cells and blood – opening a path to more personalized care with fewer side effects and a better chance of survival.
More

Gay and bisexual men living with prostate cancer focus of research

Vancouver, September 25, 2018 – Research funded by Prostate Cancer Canada is preparing the way to improve quality of life for men-who-have-sex-with-men (MSM)1 in the LGBTQ2+ community.
More


Click here for news archive